# PegIFN Alfa-2a and RBV for 16 or 24 Weeks in Patients With Chronic Hepatitis C(CHC) 2 With Rapid Virologic Response(RVR)

> **NCT01056172** · PHASE4 · UNKNOWN · sponsor: **Pusan National University Yangsan Hospital** · enrollment: 164 (estimated)

## Conditions studied

- Chronic Hepatitis C

## Interventions

- **DRUG:** Peginterferon alfa-2a and Ribavirin
- **DRUG:** Peginterferon alfa-2a and Ribavirin

## Key facts

- **NCT ID:** NCT01056172
- **Lead sponsor:** Pusan National University Yangsan Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2010-01
- **Primary completion:** 2012-06
- **Final completion:** 2012-12
- **Target enrollment:** 164 (ESTIMATED)
- **Last updated:** 2012-04-20

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01056172

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01056172, "PegIFN Alfa-2a and RBV for 16 or 24 Weeks in Patients With Chronic Hepatitis C(CHC) 2 With Rapid Virologic Response(RVR)". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT01056172. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*